thalidomide has been researched along with Thalassemias in 7 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy and safety of thalidomide in children with transfusion-dependent thalassemia." | 8.02 | Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia. ( Chandra, J; Goel, M; Parakh, N; Pemde, H; Sharma, S; Singh, N, 2021) |
| "To assess the efficacy and safety of thalidomide in children with transfusion-dependent thalassemia." | 4.02 | Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia. ( Chandra, J; Goel, M; Parakh, N; Pemde, H; Sharma, S; Singh, N, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Chandra, J | 2 |
| Khera, S | 1 |
| Kandasamy, D | 1 |
| Vidyasagar, S | 1 |
| Bolanthakodi, N | 1 |
| Vaidya, AK | 1 |
| Prethika, PA | 1 |
| Mohan, G | 1 |
| Shastry, S | 1 |
| Parakh, N | 1 |
| Singh, N | 1 |
| Sharma, S | 1 |
| Goel, M | 1 |
| Pemde, H | 1 |
| Kalra, M | 1 |
| Khanna, VK | 1 |
| Trehan, A | 1 |
| Mahajan, A | 1 |
| Fozza, C | 1 |
| Pardini, S | 1 |
| Giannico, DB | 1 |
| Targhetta, C | 1 |
| Di Tucci, AA | 1 |
| Dessalvi, P | 1 |
| Angelucci, E | 1 |
| Dore, F | 1 |
| Ricchi, P | 1 |
| Costantini, S | 1 |
| Spasiano, A | 1 |
| De Dominicis, G | 1 |
| Di Matola, T | 1 |
| Cinque, P | 1 |
| Ammirabile, M | 1 |
| Marsella, M | 1 |
| Filosa, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia: a Quasi Randomized Control Trial in a Tertiary Care Hospital in Bangladesh[NCT06098014] | Phase 3 | 60 participants (Anticipated) | Interventional | 2023-03-08 | Recruiting | ||
| Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia Patients of Pakistan[NCT03651102] | Phase 2/Phase 3 | 654 participants (Actual) | Interventional | 2018-01-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 other studies available for thalidomide and Thalassemias
| Article | Year |
|---|---|
Safety: A Primary Concern in Thalidomide Use in Thalassemia: Reply.
Topics: beta-Thalassemia; Humans; Thalassemia; Thalidomide | 2021 |
Safety: A Primary Concern in Thalidomide Use in Thalassemia.
Topics: beta-Thalassemia; Humans; Thalassemia; Thalidomide | 2021 |
Unveiling the masked native blood group following thalidomide therapy in a thalassemia patient: A 5 WHY analysis approach.
Topics: Adult; Blood Group Antigens; Blood Grouping and Crossmatching; Female; Humans; Pregnancy; Rh-Hr Bloo | 2022 |
Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia.
Topics: Adolescent; beta-Thalassemia; Child; Hemoglobins; Humans; Prospective Studies; Thalassemia; Thalidom | 2021 |
Thalidomide in Transfusion Dependent Thalassemia: Hope or Hype.
Topics: Blood Transfusion; Child; Humans; Immunosuppressive Agents; Male; Thalassemia; Thalidomide; Treatmen | 2017 |
Dramatic erythroid response to low-dose thalidomide in two patients with transfusion independent thalassemia and severe post-transfusional alloimmune hemolysis.
Topics: Aged; Anemia, Hemolytic; Antibodies, Monoclonal, Murine-Derived; Blood Transfusion; Female; Hemolysi | 2015 |
The long-term and extensive efficacy of low dose thalidomide in a case of an untransfusable patient with Non-Transfusion-Dependent Thalassemia.
Topics: Antisickling Agents; Blood Transfusion; Bone Marrow; Drug Administration Schedule; Female; Fetal Hem | 2016 |